Abstract:A specific variant in the PNPLA3 gene is a known genetic risk factor for NAFLD. We validated an antibody recognizing the PNPLA3 protein and used it to show that the PNPLA3 protein is primarily located on hepatic lipid droplets in human liver samples from patients with NAFLD. We also showed that PNPLA3 protein levels are associated with NAFLD and that carriers of the specific PNPLA3 gene variant had higher hepatic levels of the protein compared to subjects without the mutation. The hypothesis that increased hepatic PNPLA3 protein levels in subjects carrying the mutation contributes to their increased risk of NAFLD is supported. In nonalcoholic fatty liver disease (NAFLD) the patatin‐like phospholipase domain‐containing 3 (PNPLA3) rs738409 variant is a contributor. In mice, the Pnpla3 148M variant accumulates on lipid droplets and probably leads to sequestration of a lipase cofactor leading to impaired mobilization of triglycerides. To advance our understanding of the localization and abundance of PNPLA3 protein in humans, we used liver biopsies from patients with NAFLD to investigate the link to NAFLD and the PNPLA3 148M genotype. We experimentally qualified an antibody against human PNPLA3. Hepatic PNPLA3 protein fractional area and localization were determined by immunohistochemistry in biopsies from a well‐characterized NAFLD cohort of 67 patients. Potential differences in hepatic PNPLA3 protein levels among patients related to degree of steatosis, lobular inflammation, ballooning, and fibrosis, and PNPLA3 I148M gene variants were assessed. Immunohistochemistry staining in biopsies from patients with NAFLD showed that hepatic PNPLA3 protein was predominantly localized to the membranes of small and large lipid droplets in hepatocytes. PNPLA3 protein levels correlated strongly with steatosis grade (p = 0.000027) and were also significantly higher in patients with lobular inflammation (p = 0.009), ballooning (p = 0.022), and significant fibrosis (stage 2–4, p = 0.014). In addition, PNPLA3 levels were higher in PNPLA3 rs738409 148M (CG, GG) risk allele carriers compared to 148I (CC) nonrisk allele carriers (p = 0.0029). Conclusion: PNPLA3 protein levels were associated with increased hepatic lipid content and disease severity in patients with NAFLD and were higher in PNPLA3 rs738409 (148M) risk allele carriers. Our hypothesis that increased hepatic levels of PNPLA3 may be part of the pathophysiological mechanism of NAFLD is supported.

PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells

PNPLA3 148M/M Is More Susceptible to Palmitic Acid-Induced Endoplasmic Reticulum Stress-Associated Apoptosis in HepG2 Cells

PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction

The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells

PNPLA3 Rs139051 is Associated with Phospholipid Metabolite Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease

Overexpression of Variant PNPLA3 Gene at I148M Position Causes Malignant Transformation of Hepatocytes Via IL-6-JAK2/STAT3 Pathway in Low Dose Free Fatty Acid Exposure: a Laboratory Investigation in Vitro and in Vivo.

PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with ATGL

PNPLA3-I148M is a Neomorph that Interferes with Two Primary Hepatic Triglyceride Clearance Pathways

Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans

PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis

Pdia3 Knockdown Exacerbates Free Fatty Acid-Induced Hepatocyte Steatosis and Apoptosis

Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation

PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein

Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk

PNPLA3, CGI‐58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice

The PNPLA3 variant I148M reveals protective effects toward hepatocellular carcinoma in mice via restoration of omega-3 polyunsaturated fats

The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics

Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis

The influence of patatin-like phospholipase domain-containing protein 3 on palmitic acid-induced hepatocyte apoptosis

Accumulation of PNPLA3 on Lipid Droplets is the Basis of Associated Hepatic Steatosis

Long‐term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals